Pharmacia year-end results
This article was originally published in The Tan Sheet
Executive Summary
Consumer healthcare sales up 10.6% to $229 mil. in fourth quarter and 13.3% to $829 mil. for the year, "representing a second consecutive year of double-digit sales growth," firm reports Feb. 19. Gains were driven by "strong growth" in Nicorette smoking cessation franchise, which recorded sales increases of 15% in Q4 and 31% for the year. Pharmacia's total sales were flat at $3.74 bil. in the quarter and $13.99 bil. in 2002. On a reported basis, net earnings leapt to $554 mil. in Q4 from $86 mil. the previous year, spurred by one-time gain of $100 mil. from a patent infringement settlement with Allergan, $26 mil. from product licensing rights. Net earnings for 2002 dipped 60.2% to $1.5 bil. Firm's acquisition by Pfizer expected to close in Q1 2003 (1"The Tan Sheet" Jan. 27, 2003, p. 5)...
You may also be interested in...
Pfizer/Pharmacia Consumer Product Divestitures Addressing Overlaps – Exec
Overlapping consumer product categories appear to be delaying U.S. and EU regulatory approval of Pfizer's acquisition of Pharmacia
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.